Decades after Bernie Sanders first ran bus trips to Canada, President Biden has a bipartisan opportunity to end drugmakers' ability to lock Americans out of lower-priced medicine.
Biden said he'd offer a public option for health insurance. He didn't—leaving states on their own to fight some of the nation's largest, richest and most politically organized businesses.
People in the businesses of health and wellness have every reason to launch new and bigger efforts to reach consumers across every platform available, providing engaging, credible content that stands out amid the noise.
President Joe Biden caved to political pressure from congressional Democrats on Wednesday, announcing that he plans to back a proposal to waive intellectual property rights for COVID-19 vaccines.
In developing its vaccine, Pfizer was doing what the private sector does best: thrive under pressure and respond to market demands as no government agency can.
In the weeks before and after the Montana Republican threw his weight behind the proposal, he received a total of $18,500 from seven different Big Pharma political action committees.
Rep. Rashida Tlaib (D-Mich.) accused the CEO of drug company Teva of pretending to "look like you give a shit about sick people" while making ever-increasing profits during House testimony on Wednesday.
The pharmaceutical industry is donating large amounts to Biden's campaign but there are doubts he'll deliver on prescription drug prices.
Through aggressive promotion and selective media leaks to inflate their stock prices, pharmaceutical company executives and insiders are profiteering from the pandemic. Congress must stop them.
Americans have good reason to be skeptical that Big Pharma will be our savior in this crisis—unless our fellow Republicans and Democrats in Congress intervene.
There is growing bipartisan agreement that we need to bring pharmaceutical production back home. But one enormous hurdle remains.
In his weekly round-up of business and economic news, Newsweek editorial director Hank Gilman gives the lowdown on AOC vs. Cramer, pharma shortages and the future of shopping
Researchers have compared the profit margins of America's drug companies, finding they are comparable with technology companies and higher than most industries.
A drug looking to relieve symptoms of the autoimmune disease lupus by blocking receptors for the immune protein has just completed its third clinical trial.
Following major recalls of Chinese-manufactured medication that contained carcinogenic ingredients, lawmakers expressed their alarm, and sometimes disbelief, at the FDA's inability to regulate foreign suppliers at a Tuesday hearing.
At a time when drugs can take a decade from discovery to market, and as Big Pharma develops fewer drugs, a growing number of researchers are betting on old drugs.
Miami-Dade County became the latest in a slew of counties and cities seeking litigation against the pharmaceutical industry for its alleged role in the opioid crisis.
Investigators are closing in on Big Pharma, claiming that shady tactics fueled the opioid crisis.
Psychiatric medications are being overprescribed, but in some cases, these drugs save lives. We need a more nuanced approach to treatment.
Democracy Forward is suing for details about a former pharmaceutical lobbyist's role in drug regulation.
The use of nitroprusside and isoproterenol dropped by 53 percent and 35 percent over three years, as their prices skyrocketed by factors of ten.